Atrial fibrillation

Omega-3 fish oil supplements have a well-documented upside for cardiovascular health, but they carry one genuine adverse effect that the evidence supports clearly: a higher risk of atrial fibrillation (AFib), the most common abnormal heart rhythm.

The risk is real, and it scales with dose

A 2021 meta-analysis of cardiovascular-outcome trials found that omega-3 supplementation raised AFib risk by roughly 25% across studies when pooled [1]. The signal sharpens when you separate doses: at around 1 g/day, risk rose approximately 12%; at 1.8-4 g/day, it rose approximately 50% [1]. That dose-response pattern matters. It means the risk isn't a flat background hum, it climbs as the amount goes up.

Verhoeven's analysis suggests the underlying mechanism involves omega-3 fatty acids incorporating into cardiomyocyte cell membranes, increasing their fluidity and altering ion channels, including Piezo mechanosensors and sodium/calcium channels, as well as sodium-potassium pump function [2]. At high membrane concentrations, these changes can set off arrhythmia. This is a plausible biological explanation, though it remains a synthesis rather than settled mechanistic proof.

A strange paradox in the data

A large UK Biobank prospective cohort study (415,737 participants, 11.9 years of follow-up) added a complicating layer [3]. Fish oil users who had no prior heart disease developed AFib at a higher rate than non-users (hazard ratio 1.13), and had a modestly higher stroke rate (HR 1.05). So far, that confirms the harm signal.

The twist: among people who already had AFib or cardiovascular disease at baseline, fish oil users had a lower rate of subsequent heart attack (HR 0.85) and major adverse cardiovascular events (HR 0.92) [3]. Verhoeven's analysis describes this as an "AFib-then-protective" paradox, suggesting fish oil may accelerate the transition into AFib in susceptible individuals while simultaneously dampening the downstream consequences once disease is established [4]. Whether that tradeoff is acceptable depends entirely on individual risk profile, a judgment that belongs with a clinician.

Both effects coexist

The AFib risk and the cardiovascular benefit are not mutually exclusive findings from separate literatures. They appear in overlapping datasets and point toward a U-shaped dose-response for omega-3 supplementation [2]. A modest dose in a low-AFib-risk individual looks different from a high dose in someone with existing atrial vulnerability.

Verhoeven's analysis caps suggested omega-3 intake at around 2 g/day partly on the basis of this dose-dependent AFib signal [2], though this represents an analyst's interpretation, not a regulatory guideline or a finding from a single primary trial.

Where the evidence is contested

The core AFib finding from the Gencer 2021 meta-analysis [1] draws from large cardiovascular-outcome RCTs where many participants were already at improved cardiac risk. Whether the same risk magnitude applies to otherwise healthy adults taking low-dose fish oil is not clearly established by the data on this page.

The UK Biobank result [3] is observational. People who chose to take fish oil may differ systematically from those who didn't, and the "lower MACE once in AFib" finding could reflect confounding rather than a true protective effect in disease. Verhoeven's synthesis treats the paradox as a coherent pattern [4], but a more cautious reading would note that prospective cohort data cannot establish causation in either direction with confidence.

References

1. Gencer 2021 (Circulation) — omega-3 & AFib meta
2. Analyst/expert source (S042) — see our methodology
3. Chen G et al. 2024 (BMJ Med 3:e000451) — UK Biobank; n=415,737; 11.9 yr; fish oil → ↑AFib (HR 1.13), ↑stroke (HR 1.05); BUT AF→MI HR 0.85, AF→MACE… · PubMed 38800667
4. Analyst/expert source (S046) — see our methodology